OKYO Pharma Ltd ADR
$ 1.67
-1.76%
24 Feb - close price
- Market Cap 89,890,000 USD
- Current Price $ 1.67
- High / Low $ 1.72 / 1.52
- Stock P/E N/A
- Book Value -0.15
- EPS -0.12
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.70 %
- ROE -29.69 %
- 52 Week High 3.35
- 52 Week Low 1.03
About
OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye pain in the UK. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$10.00
Quarterly Earnings
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-08-05 | 2025-03-31 | 2025-01-29 | 2024-09-30 | 2024-07-30 | 2024-03-31 | 2024-01-09 | 2023-12-28 | 2023-08-15 |
| Reported EPS | -0.06 | None | -0.08 | None | -0.09 | None | -0.1 | -0.11 | -0.34 |
| Estimated EPS | -0.05 | -0.05 | -0.09 | -0.09 | -0.09 | -0.09 | -0.1 | -0.11 | -0.11 |
| Surprise | -0.01 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | -0.23 |
| Surprise Percentage | -20% | None% | 11.1111% | None% | 0% | None% | 0% | 0% | -209.0909% |
Next Quarterly Earnings
| Feb 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OKYO
2026-02-23 15:46:50
OKYO Pharma's urcosimod, a non-opioid eye-drop therapy for neuropathic corneal pain (NCP), has been selected for presentation at the ARVO 2026 Annual Meeting following positive Phase 2a trial results. The study demonstrated significant pain reduction and improved quality of life for NCP patients, a condition currently lacking FDA-approved treatments. OKYO Pharma plans to advance urcosimod, which has FDA Fast Track designation, into a larger multicenter Phase 2b/3 trial.
2026-02-23 15:42:43
OKYO Pharma announced that its experimental eye drop, urcosimod, for neuropathic corneal pain (NCP) showed clinically meaningful pain reduction and quality-of-life improvements in a Phase 2a trial. The data will be presented at ARVO 2026. Urcosimod has FDA Fast Track designation and is the first candidate to receive IND clearance for NCP, with a larger Phase 2b/3 trial expected to start soon.
2026-02-23 15:42:43
OKYO Pharma Limited announced that its abstract, detailing positive results from the Phase 2a clinical trial of urcosimod for neuropathic corneal pain (NCP), has been selected for presentation at the ARVO 2026 Annual Meeting. The trial showed clinically meaningful pain reduction and quality-of-life improvements, alongside potential to restore corneal nerve structure in NCP patients, a condition with no FDA-approved treatments. OKYO plans to advance urcosimod, which has FDA Fast Track designation, into a larger Phase 2b/3 trial soon.
2026-02-20 13:56:15
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) has received an average "Hold" recommendation from five ratings firms, with an average 12-month target price of $6.00. The company's stock recently opened at $1.76, and institutional investors have adjusted their holdings, with Renaissance Technologies LLC significantly increasing its stake. OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and fibrotic diseases.
2026-02-13 17:58:28
OKYO Pharma Limited announced its intention to conduct an underwritten public offering of its ordinary shares, which will be sold by the company. The proceeds are intended for clinical development of product candidates, general corporate purposes, and working capital. Piper Sandler & Co. is acting as the sole book-running manager, and the offering is subject to market conditions.
2026-02-13 03:28:19
OKYO Pharma Limited (Nasdaq: OKYO) announced the pricing of an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, aiming to raise approximately $20 million. The company has granted the underwriter an option to purchase additional shares. Proceeds from the offering will primarily fund clinical development of its product candidates, general corporate purposes, and working capital.
